Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis

Next Previous
X
Search
Trial Profile

Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics (Primary) ; Leukocyte-cell-therapy-Enlivex-Therapeutics (Primary)
  • Indications Peritoneal cancer
  • Focus Adverse reactions
  • Sponsors Enlivex Therapeutics

    • Most Recent Events

    • 15 Apr 2024 Status changed from recruiting to discontinued.
    • 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Apr 2023 According to an Enlivex Therapeutics media release, complete of enrollment and data readouts are expected by Q2 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top